Misplaced Pages

Ateganosine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 17:56, 30 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits created drug stubTag: nowiki added  Latest revision as of 00:56, 2 January 2025 edit undoCitation bot (talk | contribs)Bots5,435,997 edits Added bibcode. | Use this bot. Report bugs. | Suggested by Graeme Bartlett | #UCB_toolbar 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Orphan|date=December 2024}}

{{cs1 config|name-list-style=vanc|display-authors=6}} {{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
Line 18: Line 20:
| widthR = | widthR =
| altR = | altR =
| captionLR = | captionLR =


<!-- Clinical data --> <!-- Clinical data -->
Line 39: Line 41:
| ATC_prefix = | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =


<!-- Legal status --> <!-- Legal status -->
Line 60: Line 62:
| legal_UN = | legal_UN =
| legal_UN_comment = | legal_UN_comment =
| legal_status = | legal_status =


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 70: Line 72:
| elimination_half-life = | elimination_half-life =
| duration_of_action= | duration_of_action=
| excretion = | excretion =


<!-- Identifiers --> <!-- Identifiers -->
| CAS_number = 789-61-7 | CAS_number = 789-61-7
| CAS_supplemental =
| PubChem = 3000603 | PubChem = 3000603
| PubChemSubstance =
| IUPHAR_ligand = | IUPHAR_ligand =
| DrugBank = | DrugBank = DB18117
| ChemSpiderID = | ChemSpiderID = 2272164
| UNII = KR0RFB46DF | UNII = KR0RFB46DF
| KEGG = | KEGG =
Line 86: Line 86:
| NIAID_ChemDB = | NIAID_ChemDB =
| PDB_ligand = | PDB_ligand =
| synonyms = | synonyms = 2'-Deoxythioguanosine


<!-- Chemical and physical data --> <!-- Chemical and physical data -->
Line 108: Line 108:
| specific_rotation = | specific_rotation =
}} }}
'''Ateganosine''' is a ] inhibitor<ref name="Eglenen-Polat_2024">{{cite journal | vauthors = Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, Bender ME, Mender I, Stastny V, Drapkin BJ, Raj P, Minna JD, Xu L, Shay JW, Akbay EA | title = A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | journal = Nature Communications | volume = 15 | issue = 1 | pages = 672 | date = January 2024 | pmid = 38253555 | pmc = 10803750 | doi = 10.1038/s41467-024-44861-8 | url = }}</ref> and ] inducer currently under investigation for the treatment of various cancers, including ] (NSCLC).<ref>{{cite web | title = Ateganosine | url = https://synapse.patsnap.com/drug/e50d8d1b96bf47c99f827aba2d529c89 | work = PatSnap }}</ref> '''Ateganosine''' is a ] inhibitor<ref name="Eglenen-Polat_2024">{{cite journal | vauthors = Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, Bender ME, Mender I, Stastny V, Drapkin BJ, Raj P, Minna JD, Xu L, Shay JW, Akbay EA | title = A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer | journal = Nature Communications | volume = 15 | issue = 1 | pages = 672 | date = January 2024 | pmid = 38253555 | pmc = 10803750 | doi = 10.1038/s41467-024-44861-8 | bibcode = 2024NatCo..15..672E | url = }}</ref> and ] inducer currently under investigation for the treatment of various cancers, including ] (NSCLC).<ref>{{cite web | title = Ateganosine | url = https://synapse.patsnap.com/drug/e50d8d1b96bf47c99f827aba2d529c89 | work = PatSnap }}</ref>


== References == == References ==
{{reflist}} {{reflist}}

⚫ {{pharma-stub}}


] ]
Line 119: Line 117:
] ]
] ]
]


⚫ {{pharma-stub}}

Latest revision as of 00:56, 2 January 2025

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Ateganosine
Clinical data
Other names2'-Deoxythioguanosine
Identifiers
IUPAC name
  • 2-amino-9--3H-purine-6-thione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13N5O3S
Molar mass283.31 g·mol
3D model (JSmol)
SMILES
  • C1((O1N2C=NC3=C2NC(=NC3=S)N)CO)O
InChI
  • InChI=InChI=1S/C10H13N5O3S/c11-10-13-8-7(9(19)14-10)12-3-15(8)6-1-4(17)5(2-16)18-6/h3-6,16-17H,1-2H2,(H3,11,13,14,19)/t4-,5+,6+/m0/s1
  • Key:SCVJRXQHFJXZFZ-KVQBGUIXSA-N

Ateganosine is a telomerase inhibitor and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).

References

  1. Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1): 672. Bibcode:2024NatCo..15..672E. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.
  2. "Ateganosine". PatSnap.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: